Analytical Data
-
Gene name
BETVII
- Application
-
Alternative Names
Allergen Bet v II Pollen allergen Bet v 2 Allergen: Bet v 2
-
Species
Betula pendula
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P25816
-
Expression Region
2-133aa
-
Molecular Weight
30.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of BETVII recombinant protein has gained significant attention due to its potential implications in various biological and therapeutic applications. Bromodomain and Extra-Terminal domain (BET) proteins are recognized as key regulators of gene expression and cellular processes associated with cancer, inflammation, and cardiovascular diseases. BETVII, a member of this protein family, functions by interacting with acetylated lysine residues on histones, thereby influencing chromatin dynamics and transcriptional activity. Research has shown that targeting BET proteins can modulate the expression of oncogenes involved in tumor development and progression. Furthermore, BETVII has been implicated in the regulation of immune responses and stem cell biology, highlighting its multifaceted role in both normal physiology and disease states. The ability to produce recombinant BETVII protein allows for in-depth characterization of its structure, function, and interaction with various ligands and biomolecules, paving the way for the development of novel therapeutic strategies. Given the promise of BET proteins as drug targets, ongoing studies aim to elucidate the precise mechanisms of BETVII in pathological contexts and explore its potential as a biomarker for disease prognosis and treatment response. Overall, the research on BETVII recombinant protein is pivotal in advancing our understanding of epigenetic regulation and developing innovative approaches to combat various diseases.
